Found 43 Enz. Inhib. hit(s) with all data for entry = 8181 TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: 2nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: 3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: <10nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: 23nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: 37nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: 48nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: 50nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: 90nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: 129nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: 132nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: 153nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: 166nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: 182nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: 195nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: 215nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: 227nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: 373nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: 554nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: 556nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: 657nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: 920nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: >1.00E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: >1.00E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: >1.00E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: >1.00E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: 1.10E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: 1.21E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: 1.24E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: 1.30E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: 1.50E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: 1.52E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: 1.53E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: 1.89E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: 1.90E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: 2.83E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: 3.24E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: 3.58E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: 6.27E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: 9.20E+3nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetGlycogen synthase kinase-3 beta(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: >1.00E+4nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: >1.00E+4nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: >1.00E+4nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Johannes Gutenberg-UniversitäT Mainz
US Patent
Johannes Gutenberg-UniversitäT Mainz
US Patent
Affinity DataIC50: >1.00E+4nMAssay Description:The effect of test compounds on the activity of the protein kinases GSK-3β, VEGFR-2 and FLT-3 was evaluated based on half maximal inhibitory con...More data for this Ligand-Target Pair
